Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Pre menopausal female adults with confirmed length and regular menstrual cycle~* Surgically diagnosed endometriosis~* Moderate to severe endometriosis related pain~Exclusion Criteria:~* Hormonal contraceptives or other drugs with effects on gynecological endocrinology~* Surgery for endometriosis within the 4 weeks prior to entry~* Uterine myoma~* Abnormal vaginal bleeding~* Hysterectomy or bilateral oophorectomy~* Pelvic infection~* Relevant abnormalities at gynecological exam at screening~* Disease with chronic abdominal pain of non-endometriosis origin~* Pituitary adenoma

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)
- ASP1707 lowest dose (Type: EXPERIMENTAL): Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
- ASP1707 low dose (Type: EXPERIMENTAL): Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
- ASP1707 medium dose (Type: EXPERIMENTAL): Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
- ASP1707 high dose (Type: EXPERIMENTAL): Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
- Leuprorelin acetate (Type: ACTIVE_COMPARATOR): Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).